drugset / Trial / NCT06671392
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
RandomizedParallel-groupDouble-blindTreatment
Summary
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential Hypertension Inadequately Controlled with DWC202405
Timeline
- Start
- 2025-02-24
- Primary completion
- 2026-02-05
- Completion
- 2026-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DWC202313 | Unknown | 10 mg | Oral |
| Subject | DWC202313 | Unknown | 40 mg | Oral |
| Subject | DWC202314 | Unknown | 1.5 mg | Oral |
| Subject | DWC202405 | Unknown | 5 mg | Oral |
| Subject | DWC202405 | Unknown | 20 mg | Oral |